Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
XWELLXWEL 27 FCF Yield % is -150.87 as of Aug. 24, 2026. GuruFocus rates XWEL with a GF Score™ of 27/100 and a GF Value™ of $0.86 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 213 Medical Diagnostics & Research companies, XWELL ranks worse than 96.71% on this metric.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
As of today, XWELL's Trailing 12-Month Free Cash Flow is $-13.48 Mil, and Market Cap is $8.93 Mil. Therefore, XWELL's FCF Yield % for today is -150.87%.
The historical rank and industry rank for XWELL's FCF Yield % or its related term are showing as below:
XWEL'
s FCF Yield % Range Over the Past 10 Years
Min: -638.89 Med: -113.13 Max: 23.83
Current: -150.87
During the past 13 years, the highest FCF Yield % of XWELL was 23.83%. The lowest was -638.89%. And the median was -113.13%.
XWEL's FCF Yield % is ranked worse than 96.71% of 213
companies
in the Medical Diagnostics & Research industry
Industry Median: -0.43
vs XWEL: -150.87
XWELL's FCF Margin % for the quarter that ended in Jun. 2026 was -65.56%.
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
XWELL FCF Yield % Related Terms
XWELL FCF Yield % Historical Data
* Premium members only.
The historical data trend for XWELL's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, XWELL's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
XWELL FCF Yield % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, XWELL's FCF Yield % distribution charts can be found below:
* The bar in red indicates where XWELL's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XWELL (XWEL) has a FCF Yield % of -150.87 as of Aug. 24, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on XWELL and its competitors. According to the industry distribution chart, XWELL ranks #206 out of 213 companies in the Medical Diagnostics & Research industry, placing it in the top 96.7%.
Is XWELL's FCF Yield % too high?
XWELL's current FCF Yield % is -150.87. Based on the distribution chart, XWELL ranks #206 out of 213 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, XWELL has a GF Score™ of 27/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does XWELL's FCF Yield % compare to MBAI and NDRA?
According to the Medical Diagnostics & Research industry distribution chart, XWELL ranks #206 out of 213 companies for FCF Yield %. This places XWELL in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Medical Diagnostics & Research company?
A good FCF Yield % depends on the Medical Diagnostics & Research industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on XWELL and its competitors. XWELL's current FCF Yield % is -150.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is XWELL stock overvalued right now?
Based on GuruFocus' analysis, XWELL (XWEL) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.86, compared to a current price of $1.04 — trading 20.9% above its estimated fair value. The current FCF Yield % is -150.87. XWELL's overall GF Score™ is 27/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For XWELL (XWEL), the current FCF Yield % is -150.87 as of Aug. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is XWELL (XWEL) Overvalued in 2026?
Based on GuruFocus' analysis, XWELL stock appears to be overvalued.
The current stock price of $1.04 is trading 20.9% above its estimated GF Value™ of $0.86.
GuruFocus considers XWELL to be Modestly Overvalued.
Key valuation signals for XWEL:
FCF Yield %: -150.87
GF Value™: $0.86 vs. price of $1.04 (20.9% above fair value)
No single metric tells the full story. See the XWEL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
XWELL Inc is an international wellness organization dedicated to delivering restorative and health-focused services to travelers through its three reportable operating segments: XpresSpa, XpresTest, and Naples Wax Center. The XpresSpa segment, which generates maximum revenue, operates spa service locations in airports, offering massage, skincare, and travel products. The XpresTest segment provides aircraft wastewater and passenger nasal sampling through the CDC's bio-surveillance program. The Naples Wax Center segment operates six locations offering face and body waxing, skincare services, and cosmetic products. The Company generates maximum revenue from the United States.
27GF Score
Get the complete analysis for XWEL
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XWEL has been successfully added to your 
